Abstract Background In 2004, Ethiopia adopted artemether-lumefantrine (AL, Coartem®) as
first-line treatment for the management of uncomplicated Plasmodium falciparum malaria …

Background Malaria is a complex disease, which varies in its epidemiology and clinical
manifestation. Although artemether-lumefantrine has been used as first-line drug for …

Background Plasmodium falciparum accounts for approximately 60% of malaria cases in
Ethiopia and artemether–lumefantrine has been used as a first-line treatment for …

Background Artemether–lumefantrine (AL) has been used as a first-line treatment for
uncomplicated Plasmodium falciparum malaria in Ethiopia since 2004. Antimalarial drug …

Purpose Following the increased Plasmodium falciparum resistance to chloroquine and
sulfadoxine/pyrimethamine, Ethiopia adopted artemether/lumefantrine (AL) as the first-line …

Background The efficacy of artemether-lumefantrine (AL) for treatment of uncomplicated
Plasmodium falciparum malaria in south-western Ethiopia is poorly documented. Regular …

Introduction. Multidrug resistance of Plasmodium falciparum is spreading throughout Africa.
This has posed major challenges to malaria control in sub‐Saharan Africa. Objective. The …

Abstract Background Artemether/Lumefantrine (Coartem®) has been used as a first-line
treatment for uncomplicated Plasmodium falciparum infection since 2004 in Ethiopia. In the …

Background In vivo efficacy assessments of the first-line treatments for Plasmodium
falciparum malaria are essential for ensuring effective case management. In Ethiopia …

Background Malaria remains a major global health problem although there was a
remarkable achievement between 2000 and 2015. Malaria drug resistance, along with …